Compare NP & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | AAPG |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | China |
| Employees | 58 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | N/A | N/A |
| Metric | NP | AAPG |
|---|---|---|
| Price | $24.47 | $26.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $27.04 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 325.5K | 2.0K |
| Earning Date | 04-29-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.45 | $388.23 |
| Revenue Next Year | $15.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.78 | $17.56 |
| 52 Week High | $31.75 | $48.45 |
| Indicator | NP | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 62.48 | 60.00 |
| Support Level | $24.29 | $25.80 |
| Resistance Level | $26.85 | $28.49 |
| Average True Range (ATR) | 1.42 | 0.51 |
| MACD | 0.37 | 0.32 |
| Stochastic Oscillator | 91.47 | 94.44 |
Neptune Insurance Holdings Inc is a high-growth, data-driven MGA that is revolutionizing the way homeowners and businesses protect against the growing risks of flooding. It offers a range of easy-to-purchase residential and commercial insurance products - including primary flood insurance, excess flood insurance, and parametric earthquake insurance - distributed through a nationwide network of agencies. It underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies, whom the company refer to as capacity providers, that manage both this risk and the associated claims handling.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.